Consolidated Statement of Financial Position
as of December 31, 2024
Consolidated Income Statement
For the period from 1 January to 31 December 2024
Consolidated Statement of Comprehensive Income
For the period from 1 January to 31 December 2024
Consolidated Statement of Cash Flows
For the period from 1 January to 31 December 2024
Consolidated Statement of Changes in Stockholders’ Equity
for the Period From 01 January to 31 December 2024
Guidance 2025

Expected Liquidity & Strategic Measures

The Company’s operational financing plan does not require any additional external financing to fund organic growth in the medium term. However, any strategic moves to further push growth and strengthen the Company’s competitive position or increase critical mass via potential company or product acquisitions, or costs for transforming the company will need to be considered separately. Evotec intends to achieve organic profitable growth as a result of its corporate strategy. 
The Company continued to increase investments in the expansion and development of individual locations in 2024. In Toulouse, it has completed the construction of its second J.POD (J.POD Toulouse, France). Given that the largest investment project - the J:POD Toulouse, France - is set to start operations in 2025, investment needs are anticipated to be lower than in 2024.

You might be interested in...

Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive disease knowledge at the molecular level, cutting-edge technologies & platforms to translate this expertise into effective precision medicines.